Aclaris Therapeutics, Inc. (ACRS) Bundle
A Brief History of Aclaris Therapeutics, Inc. (ACRS)
Company Overview
Aclaris Therapeutics, Inc. was founded in 2012 and is based in Wayne, Pennsylvania. The company focuses on the development and commercialization of innovative therapies for dermatological diseases. Aclaris is publicly traded on the NASDAQ under the ticker symbol ACRS.
Key Products and Pipeline
The company's lead product, Eskata (hydrogen peroxide), received FDA approval in 2017 for the treatment of raised seborrheic keratosis. The product was launched commercially in 2018. Other notable products in development include:
- ATI-502 for alopecia areata, currently in Phase 2 clinical trials.
- ATI-1777, an oral JAK inhibitor for various dermatologic conditions, in Phase 2 trials.
- ATI-1880, a topical treatment for psoriasis, in the preclinical stage.
Financial Performance
As of the end of 2022, Aclaris reported the following financial metrics:
| Metric | Amount |
|---|---|
| Revenue | $9.3 million |
| Net Loss | ($31.8 million) |
| Total Assets | $118.5 million |
| Cash and Cash Equivalents | $48.3 million |
| Market Capitalization (as of October 2023) | $173.5 million |
Recent Developments
In 2023, Aclaris announced a restructuring plan aimed at reducing operating expenses by approximately 30%. This decision was influenced by the need to focus resources on key pipeline products.
Stock Performance
As of October 2023, the stock performance of Aclaris Therapeutics (ACRS) has been marked by volatility:
| Year | Stock Price (Closing) |
|---|---|
| 2020 | $6.15 |
| 2021 | $8.07 |
| 2022 | $2.45 |
| 2023 (as of October 1) | $3.42 |
Strategic Partnerships
Aclaris has engaged in strategic partnerships to bolster its research and development efforts. Notably, the company entered into a collaboration with Genentech to co-develop ATI-502. Financial terms of the deal were not disclosed.
Clinical Trials and Research
Aclaris has been actively conducting clinical trials. The following table summarizes key clinical trials:
| Trial Name | Indication | Phase | Estimated Enrollment |
|---|---|---|---|
| ATI-502-101 | Alopecia Areata | Phase 2 | 300 |
| ATI-502-102 | Psoriasis | Phase 2 | 250 |
| ATI-1777-103 | Atopic Dermatitis | Phase 2 | 200 |
Market Context
The dermatology market has shown considerable growth, with the global dermatology pharmaceuticals market valued at approximately $22 billion in 2021 and projected to reach $36 billion by 2028.
A Who Owns Aclaris Therapeutics, Inc. (ACRS)
Corporate Structure
Aclaris Therapeutics, Inc. was incorporated in 2012. It is based in Wayne, Pennsylvania, and focuses on developing and commercializing novel therapeutics for dermatological diseases.
Major Shareholders
The ownership of Aclaris Therapeutics is characterized by a mix of institutional and retail investors. The latest available data from Q3 2023 indicates the following major shareholders:
| Shareholder Type | Shareholder Name | Shares Held | Percentage Ownership |
|---|---|---|---|
| Institutional Investor | BlackRock, Inc. | 3,500,000 | 11.5% |
| Institutional Investor | The Vanguard Group, Inc. | 3,000,000 | 9.7% |
| Institutional Investor | AllianceBernstein L.P. | 2,800,000 | 9.1% |
| Insider | Dr. Neal Walker (CEO) | 1,200,000 | 3.9% |
| Insider | Dr. Eliav Barr | 800,000 | 2.6% |
Recent Financial Performance
Aclaris Therapeutics reported the following financial metrics for the fiscal year 2022:
| Financial Metric | Amount (USD) |
|---|---|
| Total Revenue | 15 million |
| Net Loss | (30 million) |
| Total Assets | 50 million |
| Total Liabilities | 25 million |
| Cash and Cash Equivalents | 10 million |
Market Capitalization
As of October 2023, Aclaris Therapeutics has a market capitalization of approximately $300 million.
Recent Developments
In Q3 2023, Aclaris Therapeutics announced key developments:
- Received FDA approval for a new topical treatment.
- Reported progress in several clinical trials for its pipeline products.
- Raised an additional $20 million through a recent public offering.
Stock Performance
As of the end of October 2023, Aclaris Therapeutics stock (ACRS) was trading at approximately $3.25 per share, reflecting a year-to-date increase of 35%.
Aclaris Therapeutics, Inc. (ACRS) Mission Statement
Corporate Overview
Aclaris Therapeutics, Inc. is a clinical-stage biotechnology company focused on identifying, developing, and commercializing innovative therapeutics for dermatological and immunological diseases. The company’s mission is to leverage its expertise in dermatology to create new treatment options that deliver significant clinical value to patients.
Mission Statement
The mission statement of Aclaris Therapeutics centers around the commitment to "transform the treatment of dermatological and immunological diseases through innovation." This reflects their aim to develop effective therapies that are not only groundbreaking but also improve the quality of life for individuals affected by such conditions.
Core Values
- Innovation: The pursuit of novel solutions in therapeutics.
- Integrity: Commitment to ethical practices in research and business.
- Excellence: Striving for the highest quality in all aspects of operations.
- Collaboration: Working with partners, patients, and healthcare providers to enhance healthcare outcomes.
Recent Financial Performance
Aclaris Therapeutics reported the following financial metrics for the year ending December 31, 2022:
| Metric | 2022 Amount (in millions) |
|---|---|
| Revenue | $20.5 |
| Net Loss | $(30.2) |
| Research and Development Expenses | $25.8 |
| General and Administrative Expenses | $8.9 |
| Cash and Cash Equivalents | $45.6 |
Product Pipeline
Aclaris has several candidates in various stages of clinical development:
| Product Candidate | Indication | Development Stage |
|---|---|---|
| ATI-1777 | Atopic Dermatitis | Phase 2 |
| ATI-501 | Alopecia Areata | Phase 3 |
| ATI-2138 | Psoriasis | Phase 1 |
| ATI-9188 | Pruritus | Preclinical |
Market Focus and Growth Potential
The global dermatology market is projected to reach $37 billion by 2025, representing significant growth potential for Aclaris. As of 2023, the demand for innovative treatments in dermatology, particularly in conditions like eczema and psoriasis, is driving investment and development in this sector.
Commitment to Patients
Aclaris Therapeutics emphasizes its commitment to patients through robust clinical trials and patient-centric approaches in therapy development. The company aims to engage with patient advocacy groups to ensure that their perspectives inform product development and clinical strategies.
Conclusion of Mission Statement Elements
Aclaris Therapeutics’ mission statement is reflected in its innovative pipeline, commitment to ethical practices, and dedication to addressing unmet medical needs in dermatology and immunology. The integration of financial performance metrics exemplifies the ongoing efforts to balance profitability with mission-driven goals.
How Aclaris Therapeutics, Inc. (ACRS) Works
Overview of Aclaris Therapeutics
Aclaris Therapeutics, Inc. is a biopharmaceutical company specializing in the development of innovative therapeutics for dermatological conditions. It focuses on advancing therapies that target unmet medical needs and has established a unique platform for developing proprietary compounds.
Current Pipeline
Aclaris has a diverse pipeline focused on dermatological disorders. As of October 2023, the Company’s lead candidates include:
- ATI-1777: A topical treatment for alopecia areata, currently in Phase 2 trials.
- ATI-502: For the treatment of psoriasis, in Phase 2 trials.
- ATI-2175: A novel oral therapy for the treatment of atopic dermatitis, in early development.
Financial Performance
As of Q3 2023, Aclaris reported the following financial figures:
| Financial Metric | Q3 2023 | Q2 2023 | Q3 2022 |
|---|---|---|---|
| Revenue | $1.2 million | $1.5 million | $2.1 million |
| Operating Expenses | $10.2 million | $9.3 million | $8.5 million |
| Net Loss | ($9.0 million) | ($7.8 million) | ($6.4 million) |
| Cash Position | $25.4 million | $30.6 million | $33.2 million |
Partnerships and Collaborations
Aclaris has established several partnerships to enhance its research and development capabilities:
- Partnership with the University of Pennsylvania for research on dermatological diseases.
- Collaboration with Pfizer for the development of ATI-502.
Market Position and Competition
As of 2023, Aclaris’s market capitalization stands at approximately $150 million. The company's competitors include:
- Lantech Pharmaceuticals
- Sofgen Pharmaceuticals
- Dermira, Inc.
Regulatory Affairs
Aclaris Therapeutics is actively engaging with the FDA to ensure compliance and expedite the approval process for its investigational drugs. In 2023, the company submitted IND applications for multiple candidates, aiming for expedited review pathways.
How Aclaris Therapeutics, Inc. (ACRS) Makes Money
Product Revenue
Aclaris Therapeutics generates revenue primarily through the sale of its products. As of Q3 2023, the company reported a total revenue of $12.1 million for the nine months ended September 30, 2023. The main products contributing to this revenue are:
- ATOR-1015: A treatment for alopecia areata.
- AK003: An investigational therapy focused on chronic rhinosinusitis.
Research and Development Collaborations
Aclaris engages in various collaborations with other pharmaceutical companies for joint research and development. In 2022, the company entered into a partnership with Celgene that included an upfront payment of $10 million along with milestone payments potentially exceeding $200 million based on product development success.
Grants and Funding
The company also receives grants for research projects. In 2023, Aclaris secured a grant of $5 million from the National Institutes of Health (NIH) to fund ongoing research into dermatological applications.
Intellectual Property and Licensing
Aclaris holds significant intellectual property which can be monetized through licensing agreements. In 2023, the company entered a licensing deal that generated an initial payment of $3 million with potential royalties based on future sales.
| Revenue Source | Q3 2023 Amount | 2022 Partnership Payment | 2023 Grant |
|---|---|---|---|
| Product Sales | $12.1 million | N/A | N/A |
| Research Collaborations | N/A | $10 million | N/A |
| Grants | N/A | N/A | $5 million |
| Licensing Agreements | N/A | $3 million | N/A |
Market Position and Competitive Advantage
Aclaris has established a strong market position within the dermatological sector, focusing on unmet medical needs in skin conditions. The market for dermatological products is projected to reach $48.8 billion by 2025, providing ample opportunity for growth. Aclaris holds several patents, enhancing its competitive edge and enabling potential royalty agreements in the future.
Financial Performance Metrics
As of the last filing, Aclaris reported the following financial metrics:
- Net Loss for Q3 2023: $22 million
- Cash Reserves: $150 million as of September 30, 2023
- Operating Expenses: $34 million for the first nine months of 2023
Future Outlook
The outlook for Aclaris is promising, as the company continues to expand its research pipeline. With three additional product candidates in various stages of clinical trials, projected milestones could significantly increase revenue potential moving forward. The global demand for innovative treatments in dermatology is set to grow, directly benefiting Aclaris's strategic focus.
Aclaris Therapeutics, Inc. (ACRS) DCF Excel Template
5-Year Financial Model
40+ Charts & Metrics
DCF & Multiple Valuation
Free Email Support